Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel. / Myshkin, Mikhail Yu; Männikkö, Roope; Krumkacheva, Olesya A. et al.
In: Frontiers in Pharmacology, Vol. 10, 953, 04.09.2019.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel
AU - Myshkin, Mikhail Yu
AU - Männikkö, Roope
AU - Krumkacheva, Olesya A.
AU - Kulbatskii, Dmitrii S.
AU - Chugunov, Anton O.
AU - Berkut, Antonina A.
AU - Paramonov, Alexander S.
AU - Shulepko, Mikhail A.
AU - Fedin, Matvey V.
AU - Hanna, Michael G.
AU - Kullmann, Dimitri M.
AU - Bagryanskaya, Elena G.
AU - Arseniev, Alexander S.
AU - Kirpichnikov, Mikhail P.
AU - Lyukmanova, Ekaterina N.
AU - Vassilevski, Alexander A.
AU - Shenkarev, Zakhar O.
PY - 2019/9/4
Y1 - 2019/9/4
N2 - Voltage-gated sodium (NaV) channels are essential for the normal functioning of cardiovascular, muscular, and nervous systems. These channels have modular organization; the central pore domain allows current flow and provides ion selectivity, whereas four peripherally located voltage-sensing domains (VSDs-I/IV) are needed for voltage-dependent gating. Mutations in the S4 voltage-sensing segments of VSDs in the skeletal muscle channel NaV1.4 trigger leak (gating pore) currents and cause hypokalemic and normokalemic periodic paralyses. Previously, we have shown that the gating modifier toxin Hm-3 from the crab spider Heriaeus melloteei binds to the S3-S4 extracellular loop in VSD-I of NaV1.4 channel and inhibits gating pore currents through the channel with mutations in VSD-I. Here, we report that Hm-3 also inhibits gating pore currents through the same channel with the R675G mutation in VSD-II. To investigate the molecular basis of Hm-3 interaction with VSD-II, we produced the corresponding 554-696 fragment of NaV1.4 in a continuous exchange cell-free expression system based on the Escherichia coli S30 extract. We then performed a combined nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopy study of isolated VSD-II in zwitterionic dodecylphosphocholine/ lauryldimethylamine-N-oxide or dodecylphosphocholine micelles. To speed up the assignment of backbone resonances, five selectively 13C,15N-labeled VSD-II samples were produced in accordance with specially calculated combinatorial scheme. This labeling approach provides assignment for ~50% of the backbone. Obtained NMR and electron paramagnetic resonance data revealed correct secondary structure, quasi-native VSD-II fold, and enhanced ps-ns timescale dynamics in the micelle-solubilized domain. We modeled the structure of the VSD-II/Hm-3 complex by protein-protein docking involving binding surfaces mapped by NMR. Hm-3 binds to VSDs I and II using different modes. In VSD-II, the protruding β-hairpin of Hm-3 interacts with the S1-S2 extracellular loop, and the complex is stabilized by ionic interactions between the positively charged toxin residue K24 and the negatively charged channel residues E604 or D607. We suggest that Hm-3 binding to these charged groups inhibits voltage sensor transition to the activated state and blocks the depolarization-activated gating pore currents. Our results indicate that spider toxins represent a useful hit for periodic paralyses therapy development and may have multiple structurally different binding sites within one NaV molecule.
AB - Voltage-gated sodium (NaV) channels are essential for the normal functioning of cardiovascular, muscular, and nervous systems. These channels have modular organization; the central pore domain allows current flow and provides ion selectivity, whereas four peripherally located voltage-sensing domains (VSDs-I/IV) are needed for voltage-dependent gating. Mutations in the S4 voltage-sensing segments of VSDs in the skeletal muscle channel NaV1.4 trigger leak (gating pore) currents and cause hypokalemic and normokalemic periodic paralyses. Previously, we have shown that the gating modifier toxin Hm-3 from the crab spider Heriaeus melloteei binds to the S3-S4 extracellular loop in VSD-I of NaV1.4 channel and inhibits gating pore currents through the channel with mutations in VSD-I. Here, we report that Hm-3 also inhibits gating pore currents through the same channel with the R675G mutation in VSD-II. To investigate the molecular basis of Hm-3 interaction with VSD-II, we produced the corresponding 554-696 fragment of NaV1.4 in a continuous exchange cell-free expression system based on the Escherichia coli S30 extract. We then performed a combined nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopy study of isolated VSD-II in zwitterionic dodecylphosphocholine/ lauryldimethylamine-N-oxide or dodecylphosphocholine micelles. To speed up the assignment of backbone resonances, five selectively 13C,15N-labeled VSD-II samples were produced in accordance with specially calculated combinatorial scheme. This labeling approach provides assignment for ~50% of the backbone. Obtained NMR and electron paramagnetic resonance data revealed correct secondary structure, quasi-native VSD-II fold, and enhanced ps-ns timescale dynamics in the micelle-solubilized domain. We modeled the structure of the VSD-II/Hm-3 complex by protein-protein docking involving binding surfaces mapped by NMR. Hm-3 binds to VSDs I and II using different modes. In VSD-II, the protruding β-hairpin of Hm-3 interacts with the S1-S2 extracellular loop, and the complex is stabilized by ionic interactions between the positively charged toxin residue K24 and the negatively charged channel residues E604 or D607. We suggest that Hm-3 binding to these charged groups inhibits voltage sensor transition to the activated state and blocks the depolarization-activated gating pore currents. Our results indicate that spider toxins represent a useful hit for periodic paralyses therapy development and may have multiple structurally different binding sites within one NaV molecule.
KW - Cell-free expression
KW - Channelopathies
KW - Combinatorial selective labeling
KW - Gating modifier
KW - Ligand-receptor interactions
KW - NMR spectroscopy
KW - Sodium channel
KW - PERIODIC PARALYSIS
KW - channelopathies
KW - ligand-receptor interactions
KW - combinatorial selective labeling
KW - DETERGENT MICELLES
KW - cell-free expression
KW - gating modifier
KW - sodium channel
KW - GATING PORE CURRENTS
KW - MUTATIONS
KW - BACKBONE
KW - LIPID-PROTEIN NANODISCS
KW - COMPREHENSIVE SOFTWARE PACKAGE
KW - TOOL
UR - http://www.scopus.com/inward/record.url?scp=85072937673&partnerID=8YFLogxK
U2 - 10.3389/fphar.2019.00953
DO - 10.3389/fphar.2019.00953
M3 - Article
C2 - 31555136
AN - SCOPUS:85072937673
VL - 10
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 953
ER -
ID: 22849004